Albert Abad

5.5k total citations · 1 hit paper
84 papers, 4.2k citations indexed

About

Albert Abad is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Albert Abad has authored 84 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 69 papers in Oncology, 28 papers in Pulmonary and Respiratory Medicine and 18 papers in Pathology and Forensic Medicine. Recurrent topics in Albert Abad's work include Colorectal Cancer Treatments and Studies (50 papers), Cancer Treatment and Pharmacology (27 papers) and Gastric Cancer Management and Outcomes (16 papers). Albert Abad is often cited by papers focused on Colorectal Cancer Treatments and Studies (50 papers), Cancer Treatment and Pharmacology (27 papers) and Gastric Cancer Management and Outcomes (16 papers). Albert Abad collaborates with scholars based in Spain, United States and Italy. Albert Abad's co-authors include J Maestre, Eva Martinez‐Balibrea, Anna Martínez‐Cardús, José Luís Zamora Manzano, Rafael Rosell, Aurelio Ariza, R. Rosell, Agustí Barnadas, Z Skácel and Jorge Roig and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Albert Abad

79 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A Randomized Trial Comparing Preoperative Chemotherapy Plus Surgery with Surgery Alone in Patients with Non-Small-Cell Lung Cancer

1994 923 citations Aurelio Ariza, Albert Abad et al. profile →

Peers

Countries citing papers authored by Albert Abad

Since Specialization

Citations

This map shows the geographic impact of Albert Abad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Albert Abad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Albert Abad more than expected).

Fields of papers citing papers by Albert Abad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Albert Abad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Albert Abad. The network helps show where Albert Abad may publish in the future.

Co-authorship network of co-authors of Albert Abad

This figure shows the co-authorship network connecting the top 25 collaborators of Albert Abad. A scholar is included among the top collaborators of Albert Abad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Albert Abad. Albert Abad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The Air-Test score for prediction of postoperative pulmonary complications after general anaesthesia: analysis of harmonised trial data and a prospective observational cohort 2025 ·British Journal of Anaesthesia ·(unknown), (unknown), (unknown), Albert Abad, (unknown), (unknown), Miquel Ferrer, (unknown), Gerardo Tusman, Fernando Suárez-Sipmann, Carlos Ferrando	0
2	Successful Management of Immune-Mediated Myelitis in a Renal Cancer Patient: A Case Report 2025 ·Case Reports in Oncology ·(unknown), Albert Abad, (unknown), (unknown), (unknown), (unknown), (unknown)	0
3	Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 2021 ·European Journal of Surgical Oncology ·Manuel Benavides, Auxiliadora Gómez‐España, Pilar García‐Alfonso, (unknown), José María Viéitez, Fernando Rivera, María José Safont, Albert Abad, Javier Sastre, Manuel Valladares‐Ayerbes, Alfredo Carrato, Encarnación González‐Flores, Luis Robles, Antonieta Salud, Vicente Alonso-Orduña, Clara Montagut, Elena Asensio, Eduardo Díaz‐Rubio, Enrique Aranda	3
4	Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): a pharmacogenetic-based randomized phase II trial 2017 ·Annals of Oncology ·Albert Abad, Eva Martinez‐Balibrea, José María Viéitez, (unknown), Pilar Alfonso, José Luís Zamora Manzano, Bartomeu Massutí, Manuel Benavides, Alfredo Carrato, (unknown), Javier Gállego, Cristina Grávalos, (unknown), Mariano Provencio, Manuel Valladares‐Ayerbes, Ramón Salazar, Javier Sastre, Clara Montagut, Fernando Rivera, Enrique Aranda	11
5	Curcumin mediates oxaliplatin-acquired resistance reversion in colorectal cancer cell lines through modulation of CXC-Chemokine/NF-κB signalling pathway 2016 ·Scientific Reports ·Vicenç Ruiz de Porras, Sara Bystrup, Anna Martínez‐Cardús, Raquel Pluvinet, Lauro Sumoy, Lynne Howells, Mark I. James, Chinenye Iwuji, José Luís Zamora Manzano, Laura Layos, Cristina Bugés, Albert Abad, Eva Martinez‐Balibrea	113
6	Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance 2015 ·Molecular Cancer Therapeutics ·Eva Martinez‐Balibrea, Anna Martínez‐Cardús, Alba Ginés, Vicenç Ruiz de Porras, Cátia Moutinho, Laura Layos, José Luís Zamora Manzano, Cristina Bugés, Sara Bystrup, Manel Esteller, Albert Abad	261
7	Prognostic Value of the Combination of Circulating Tumor Cells Plus KRAS in Patients With Metastatic Colorectal Cancer Treated With Chemotherapy Plus Bevacizumab 2013 ·Clinical Colorectal Cancer ·Javier Sastre, Marta Vidaurreta, (unknown), Fernando Rivera, Bartomeu Massutí, (unknown), Albert Abad, Manuel Gallén, Manuel Benavides, Enrique Aranda, Eduardo Díaz‐Rubio	30
8	Innovations therapy: mammalian target of rapamycin (mTOR) inhibitors for the treatment of neuroendocrine tumors 2011 ·Cancer and Metastasis Reviews ·Jaume Capdevila, Ramón Salazar, Irene Halperín, Albert Abad, James C. Yao	37
9	Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin‐based chemotherapy 2009 ·International Journal of Cancer ·Eva Martinez‐Balibrea, Anna Martínez‐Cardús, Eva Musulén, Alba Ginés, José Luís Zamora Manzano, Enrique Aranda, Carmen Plasencia, Nouri Neamati, Albert Abad	60
10	Consensus on the treatment of pancreatic cancer in Spain 2009 ·Clinical & Translational Oncology ·Manuel Hidalgo, Albert Abad, Enrique Aranda, (unknown), Jaime Feliú, Carlos F. Gómez, Antonio Irigoyen López, Rafael López‐López, Fernando Rivera, Carmen Rubio, Javier Sastre, Josep Tabernero, Eduardo Díaz‐Rubio	4
11	Colorectal cancer metastasis resectability after treatment with the combination of oxaliplatin, irinotecan and 5-fluorouracil. Final results of a phase II study 2008 ·Acta Oncologica ·Albert Abad, Bartomeu Massutí, Antonio Antón, (unknown), (unknown), Eugenio Marcuello, José Luís Zamora Manzano, Vicente Alonso, Alfredo Carrato, (unknown), Josep Tabernero, Enrique Aranda, Fernando Rivera, Eduardo Díaz‐Rubio, (unknown)	14
12	Elderly patients with advanced colorectal cancer derive similar benefit without excessive toxicity after first-line chemotherapy with oxaliplatin-based combinations: Comparative outcomes from the 03-TTD-01 phase III study 2008 ·Critical Reviews in Oncology/Hematology ·Javier Sastre, Enrique Aranda, Bartomeu Massutí, Josep Tabernero, Manuel Chaves-Conde, Albert Abad, Alfredo Carrato, Juan José Reina, Bernardo Queralt, Auxiliadora Gómez‐España, Encarnación González‐Flores, Fernando Rivera, Ferrán Losa, Teresa García, Pedro Sánchez‐Rovira, I. Maestu, Eduardo Díaz‐Rubio	40
13	Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells 2006 ·International Journal of Oncology ·Carmen Plasencia, Eva Martinez‐Balibrea, Anna Martínez‐Cardús, David I. Quinn, Albert Abad, Nouri Neamati	63
14	Two Consecutive Phase II Trials of Biweekly Oxaliplatin plus Weekly 48-Hour Continuous Infusion of Nonmodulated High-Dose 5-Fluorouracil as First-Line Treatment for Advanced Colorectal Cancer 2005 ·Clinical Colorectal Cancer ·Albert Abad, Alfredo Carrato, Matilde Navarro, Javier Sastre, Andrés Cervantes, Antonio Antón, (unknown), Eugenio Marcuello, (unknown), Enrique Aranda, José Luís Zamora Manzano, (unknown), Eduardo Díaz‐Rubio	7
15	Carcinoma coloide de mama. Nuestra experiencia. 1999 ·Revista de Senología y Patología Mamaria ·(unknown), (unknown), Juan Alcalde, (unknown), (unknown), Albert Abad	1
16	Phase II study of Mitonafide in advanced and relapsed colorectal cancer 1996 ·Investigational New Drugs ·Albert Abad, Cristina Grávalos, Albert Font, Francisco Molina, (unknown), Xavier Fabregat, (unknown), Miguel Martín	4
17	Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer 1994 ·Journal of Clinical Oncology ·Pascal Piedbois, Marc Buyse, G.H. Blijham, Bengt Glimelius, R. Herrmann, Frank H. Valone, Robert W. Carlson, M. Machiavelli, (unknown), Albert Abad, Nicholas J. Petrelli	162
18	K-ras gene point mutation: a stable tumor marker in non-small cell lung carcinoma 1994 ·Lung Cancer ·(unknown), Rafael Rosell, (unknown), Albert Font, Aurelio Ariza, Pilar Armengol, Albert Abad, (unknown), Mariano Monzó	27
19	Phase II feasibility study of high dose epirubicin plus etoposide and cisplatin (HDEEC) regimen in small cell lung cancer 1992 ·Investigational New Drugs ·Rafael Rosell, Joan Carles, Albert Abad, José Jimeno, Isabel Moreno, Agustín Barnadas, Nuria Ribelles, (unknown)	5
20	5-fluorouracil, ifosfamide and mitomycin (FIM) combination for pancreatic-biliary tumors 1991 ·Annals of Oncology ·Albert Abad, Rafael Rosell, Agustí Barnadas, Joan Carles, Nuria Ribelles, (unknown)	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact